The approval of Yonsa was based on 2 randomized, placebo-controlled, multicenter Phase 3 studies in patients with mCRPC. The Food and Drug Administration (FDA) has approved Yonsa (abiraterone acetate; ...
A novel formulation of the prostate cancer drug abiraterone acetate – currently marketed as Zytiga - will dramatically improve the quality of life for people suffering from prostate cancer, as ...
KING OF PRUSSIA, Pa.--(BUSINESS WIRE)--Churchill Pharmaceuticals LLC (“Churchill”) today announced that positive data from the STAAR and STAAR-E clinical trials, evaluating YONSA™ (abiraterone acetate ...
New formulation of prostate cancer drug abiraterone acetate currently marketed as Zytiga significantly increases the drug's solubilization and absorption, making it more effective and far less ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results